Androgen News and Research

RSS

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation.

24 Nov 2014

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.

14 Nov 2014

ProstaCaid dietary supplement supports prostate health

A recent presentation at an international cancer research conference in Greece reviewed the body of data on ProstaCaid, a dietary supplement compound for prostate health. A number of published studies demonstrate the formula's effects in supporting prostate health against specific prostate cancer cell lines and prostate urinary symptoms.

5 Nov 2014

Study: Certain prostate cancer medications linked to cardiac death risk

A new study has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. Published in BJU International, the findings will help doctors and patients weigh the benefits and risks of the drugs.

30 Oct 2014

New combination therapy shows promise in treating prostate cancer

Like discriminating thieves, prostate cancer tumors scavenge and hoard copper that is an essential element in the body. But such avarice may be a fatal weakness.

16 Oct 2014

Endocrine Society issues updated Clinical Practice Guideline on androgens in women

The Endocrine Society today issued a Clinical Practice Guideline (CPG) advising against the use of testosterone therapy in healthy women.

5 Oct 2014

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).

30 Sep 2014

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development.

16 Sep 2014

Low free testosterone predicts prostate cancer reclassification

Lower levels of free testosterone predict an increased likelihood of disease reclassification in men with prostate cancer, researchers report.

8 Sep 2014

Study reveals treatment trends for prostate cancer in Japan

There has been a recent increase in use of radiotherapy in Japanese men newly diagnosed with prostate cancer and a concomitant decrease in use of androgen deprivation therapy, study findings indicate.

18 Aug 2014

Scientists identify mechanism by which inherited neurological disease causes muscle weakness in men

Researchers at University of California, San Diego School of Medicine have identified the mechanism by which a rare, inherited neurodegenerative disease causes often crippling muscle weakness in men, in addition to reduced fertility.

11 Aug 2014

Study takes stock of current sexual verification policies in athletics

Spanish hurdler Mar-a Jos- Mart-nez-Pati-o, who in the 1980s endured harsh global media attention when she was subjected to unscientific gender tests, is co-author of a study that takes stock of current sexual verification policies in athletics.

5 Aug 2014

Childhood obesity linked to early puberty

A new link has been identified between obesity in childhood and the lowering of the age of puberty.

28 Jul 2014

Research roundup: ACA lawsuit primer; ACA strategies in 4 states; competitive plans for those eligible for Medicare and Medicaid

In 2012, the U.S. Supreme Court upheld the constitutionality of the ACA, but that did not end attacks against the law. Since the decision in National Federation of Independent Business v. Sebelius, objecting parties have filed more than 100 cases in federal courts nationwide.

21 Jul 2014

Letrozole drug results in higher birth rates in women with PCOS

The drug letrozole results in higher birth rates in women with polycystic ovary syndrome (PCOS) than the current preferred infertility treatment drug, according to a nationwide study led by Penn State College of Medicine researchers.

10 Jul 2014

Men with prostate cancer achieve stronger muscles and remain active through playing football

Men with prostate cancer aged 43‒74 achieve bigger and stronger muscles, improve functional capacity, gain positive social experiences and the desire to remain active through playing football for 12 weeks.

20 Jun 2014

Androgen sensitivity may contribute to hypertrichosis in girls

Prepubertal girls with hypertrichosis are likely to have genetic variants of the androgen receptor known to be particularly sensitive to androgen, say researchers.

16 Jun 2014

Study examines effect of phthalate exposure in humans’ sperm epigenetics

A new three-year, $440,000 study led by environmental health scientist Richard Pilsner at the University of Massachusetts Amherst is now underway to investigate whether phthalate levels in expectant fathers have an effect on the couples' reproductive success, via epigenetic modifications of sperm DNA.

12 Jun 2014

Groundbreaking molecular imaging agent developed to trace advanced prostate cancer

Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized-but some cases simply do not respond to this treatment.

10 Jun 2014

New targets could increase effectiveness and reduce side effects linked with breast cancer treatments

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have found new targets for potential intervention in breast cancer. These new targets could eventually increase effectiveness and reduce the undesirable side effects associated with current treatments.

6 Jun 2014